By blocking the immunosuppressive signaling of PS, bavituximab has been shown to decrease TGF-β production in the tumor microenvironment, increase production of proinflammatory cytokines via Fc gamma receptor signaling, and induce antibody-dependent cellular cytotoxicity in murine tumor models 17. This evidence concerns the gene TGFB1 and neoplasm.